What Is B7-33?
B7-33 is an experimental single-chain peptide derived from the B-chain of human relaxin-2. It was designed to activate the relaxin family peptide receptor 1, usually shortened to RXFP1, while being simpler to manufacture than the natural two-chain hormone.
Researchers describe B7-33 as a functionally selective or biased RXFP1 agonist. In certain cell systems, it favoured ERK-related signalling over the cyclic-AMP response associated with full-length relaxin-2. That pattern generated interest in whether anti-fibrotic and cardiovascular actions could be retained while avoiding unwanted signalling.
The published evidence remains preclinical. B7-33 has reduced fibrosis or tissue injury in rodent models involving the heart, airways, kidneys and foreign-body response. No published human pharmacokinetic, safety or efficacy study has established what it does in people.
What kind of molecule is B7-33?
B7-33 is a linear peptide containing 27 amino-acid residues. Its sequence is:
`VIKLSGRELVRAQIAISGMSTWSKRSL`
The name reflects its relationship to the relaxin-2 B-chain, extending from the region designated B7 through an engineered C-terminal extension to position 33. It is not a complete natural relaxin hormone and is not simply purified from pregnancy tissue.
Human relaxin-2 contains an A-chain and a B-chain connected by disulphide bonds, with an additional disulphide within the A-chain. Maintaining the correct two-chain fold and three disulphide bonds makes production and quality control more complex.
B7-33 removes that architecture. A single linear chain is easier to synthesise, but it also has different receptor affinity, stability and signalling behaviour. “Derived from” does not mean interchangeable with relaxin-2.
What is relaxin-2?
Relaxin-2 is a human peptide hormone best known for its role in pregnancy. It contributes to cardiovascular, renal and connective-tissue adaptations, including changes in blood-vessel tone and extracellular-matrix remodelling.
Relaxin biology extends beyond pregnancy. RXFP1 is expressed in cardiovascular, renal, reproductive and connective tissues. Laboratory studies link the pathway with nitric oxide, matrix metalloproteinases, transforming growth factor beta and fibroblast behaviour.
Recombinant human relaxin-2 was developed as serelaxin and studied extensively in acute heart failure. That programme is important context but not direct B7-33 evidence.
What is RXFP1?
RXFP1 is a G-protein-coupled receptor with an unusually large extracellular region containing leucine-rich repeats. Full-length relaxin-2 interacts with multiple receptor regions and can activate several intracellular pathways.
Reported RXFP1 outputs include:
- cyclic AMP production
- ERK1/2 phosphorylation
- nitric-oxide signalling
- matrix metalloproteinase regulation
- changes in fibroblast differentiation and collagen turnover
Receptor activation is not a single uniform event. Different ligands can stabilise different receptor conformations, producing different mixes of downstream signals. Cell type, receptor density and experimental timing also alter the measured pattern.
What does “functionally selective” mean?
Functional selectivity, also called biased agonism, means that two ligands acting at the same receptor do not necessarily activate every downstream pathway to the same degree.
The original B7-33 paper found that the peptide could activate RXFP1 but showed different behaviour across assay systems. In cells engineered to overexpress RXFP1, B7-33 generated cyclic AMP. In cells with endogenous receptor expression, it favoured ERK1/2 phosphorylation over strong cyclic-AMP accumulation.
The researchers proposed that this bias might retain anti-fibrotic effects while reducing cyclic-AMP-associated tumour-promoting concerns attributed to relaxin signalling in some models.
That remains a hypothesis rather than a human safety result. Signalling bias measured in one cell system can change with receptor abundance, coupling proteins, dose and duration. It is too strong to call B7-33 “non-oncogenic” or inherently safer without long-term toxicology and clinical evidence.
How strongly does B7-33 bind RXFP1?
B7-33 binds RXFP1 much more weakly than full-length human relaxin-2 in the original assays. Despite weaker binding affinity, sufficiently high experimental concentrations produced functional responses.
Affinity and efficacy answer different questions. Affinity describes how readily a ligand binds; efficacy describes what it can do after forming the receptor complex. A weak-affinity ligand can still produce a response at higher exposure.
This distinction matters for translation. Higher concentrations may be needed to obtain the desired signal, potentially increasing off-target exposure and manufacturing burden. The animal experiments do not define what receptor occupancy or concentration would be safe in humans.
How was B7-33 developed?
Researchers sought a smaller RXFP1 agonist that retained relaxin's anti-fibrotic actions without requiring the natural two-chain structure.
| Period | Development |
|---|---|
| 2016 | Original study described B7-33 as a single-chain, functionally selective RXFP1 agonist |
| 2017 | Acute vascular experiments compared B7-33 with serelaxin in rodents |
| 2018 onward | Airway and lung fibrosis findings expanded the preclinical anti-fibrotic case |
| 2019 | A B7-33-releasing implant coating was studied against the foreign-body response |
| 2020 | Mouse myocardial-infarction research reported acute cardioprotection and less adverse remodelling |
| 2021 to 2023 | Renal fibrosis, cardiomyopathy, stability and smaller analogue programmes were reported |
| Current position | Preclinical research compound with no published human development programme |
The sequence of work shows ongoing scaffold research rather than progression through Phase I, II and III trials.
What did the original fibrosis experiments show?
The initial paper evaluated B7-33 in fibroblast systems and rodent disease models. It reported activation of matrix-remodelling pathways and anti-fibrotic effects comparable with relaxin-2 in selected settings.
In a mouse model of chronic allergic airways disease, B7-33 reduced airway and lung fibrosis and improved selected airway-function measures. The model used repeated allergen exposure to create inflammation and remodelling.
This is not the same as showing treatment of human asthma, idiopathic pulmonary fibrosis or chronic obstructive pulmonary disease. Those conditions have different triggers, time courses and tissue pathology. Mouse airway-function improvement is a preclinical signal, not a clinical outcome.
What has B7-33 shown after myocardial infarction?
A 2020 mouse study tested B7-33 around experimental myocardial infarction. The researchers reported reduced acute cardiomyocyte death and infarct size, followed by less fibrosis and adverse left-ventricular remodelling.
These are two related but distinct questions. Acute cardioprotection concerns how much tissue dies during the initial injury. Remodelling concerns the size, shape and function of the ventricle as scar tissue forms later.
The study used controlled experimental injury in young laboratory animals. Human myocardial infarction varies in artery, delay to reperfusion, comorbidities and concurrent medicine. There is no trial showing that B7-33 improves survival, heart-failure admission or cardiac function after a human heart attack.
A later experimental cardiomyopathy study compared B7-33, relaxin and the ACE inhibitor perindopril. B7-33 reduced left-ventricular fibrosis and preserved selected cardiac outcomes in rodents. Comparisons inside an animal model do not establish superiority to an evidence-based human heart-failure medicine.
What has B7-33 shown in blood vessels?
One study compared acute B7-33 and serelaxin exposure in male rats. Three hours after administration, researchers removed arteries and assessed their responses using wire myography.
Both ligands improved bradykinin-mediated, endothelium-dependent relaxation in mesenteric arteries, partly through endothelium-derived hyperpolarisation. The overall effect was not reproduced in the small renal artery or abdominal aorta.
A separate ex-vivo experiment exposed mouse mesenteric arteries to trophoblast-conditioned medium intended to model aspects of endothelial dysfunction in pre-eclampsia. B7-33 and serelaxin prevented the measured dysfunction.
This demonstrates vessel-bed and model-specific activity. It does not show that B7-33 treats pre-eclampsia or vascular disease in pregnant people. Pregnancy introduces placental, fetal, renal and haemodynamic safety questions that rodent vessels outside the body cannot answer.
What has B7-33 shown in kidney fibrosis?
Unilateral ureteral obstruction is a rodent model that produces rapid kidney fibrosis after one ureter is blocked. Researchers used imaging and tissue analysis to compare collagen organisation and anti-fibrotic interventions.
Relaxin and B7-33 altered collagen features, increased matrix metalloproteinase-2 and reduced tissue inhibitor of metalloproteinase-1 relative to obstruction alone. These changes are consistent with increased extracellular-matrix turnover.
The model is useful for mechanism and imaging validation, but it does not represent every form of chronic kidney disease. It also does not establish improved filtration, avoidance of dialysis or long-term organ preservation in humans.
Could B7-33 reduce scarring around implants?
The foreign-body response can create a collagen-rich capsule around implanted materials, affecting devices such as sensors and drug-delivery systems.
Researchers incorporated B7-33 into a biodegradable PLGA coating for sustained local release. In a mouse implantation model, the coating reduced fibrotic-capsule formation compared with controls.
This result belongs to the complete device-coating system. It does not establish that systemic B7-33 prevents surgical scars, improves wound healing or reverses established fibrosis throughout the body.
Why is fibrosis difficult to treat?
Fibrosis is excessive or disorganised deposition of extracellular matrix after repeated injury. Activated fibroblasts and myofibroblasts produce collagen and alter tissue architecture.
The process is not identical across the heart, lung, liver, kidney or skin. Timing matters: preventing early scar expansion is different from removing a mature, cross-linked matrix. Some scar formation is also essential after injury, particularly after myocardial infarction where the damaged wall needs mechanical strength.
An anti-fibrotic drug must therefore change pathological remodelling without causing weak tissue, bleeding, impaired repair or organ-specific harm. Reducing collagen staining in a short rodent experiment is only an early step.
Is B7-33 the same as serelaxin?
No. Serelaxin is recombinant human relaxin-2 with the natural two-chain, disulphide-linked structure. B7-33 is a shorter synthetic single chain with lower receptor affinity and a different signalling profile.
Serelaxin reached large human trials in acute heart failure. The confirmatory RELAX-AHF-2 trial enrolled 6,545 participants and did not significantly reduce either cardiovascular death at 180 days or worsening heart failure through day five.
That negative trial does not prove B7-33 will fail, because they are different ligands. It does show that promising relaxin biology and earlier signals did not guarantee clinical benefit. Serelaxin's thousands of patient exposures cannot be borrowed to claim B7-33 safety.
What is known about B7-33 stability?
Unmodified B7-33 was reported to have an in-vitro serum half-life of about six minutes. Rapid proteolysis can make sustained systemic exposure difficult and may explain the use of repeated administration or infusion systems in animal work.
A 2023 study attached a fatty acid through a spacer to create a lipidated derivative. The reported in-vitro serum half-life increased to roughly 60 minutes while selected RXFP1 activity was retained.
The lipidated molecule is not ordinary B7-33. Lipidation can change albumin binding, tissue distribution, clearance and off-target exposure. It therefore needs its own toxicology and efficacy evidence.
How is B7-33 synthesised and characterised?
A 27-residue linear peptide can be assembled by solid-phase peptide synthesis. Protected amino acids are coupled sequentially to a resin, followed by cleavage, deprotection and purification.
Removing the natural relaxin disulphide architecture simplifies production, but length still creates opportunities for deletion sequences, incomplete coupling, oxidation and aggregation. Methionine and tryptophan residues require particular attention to oxidation.
A credible analytical package can include intact-mass spectrometry, peptide mapping or sequence confirmation, chromatographic related-substance analysis, peptide content, counterions, water and a functional RXFP1 assay.
For any injectable investigational product, sterility, bacterial endotoxin, particles, concentration accuracy, container compatibility and stability are separate requirements. Research-grade powder is not a clinically validated formulation.
What is known about safety?
No published human study defines B7-33 adverse events, maximum tolerated exposure, pharmacokinetics or interaction risks.
Biologically plausible concerns include low blood pressure or altered vascular responses, effects on renal haemodynamics, changes in wound repair and unanticipated consequences of matrix degradation. RXFP1 expression in reproductive tissues creates additional questions for pregnancy and fertility.
The original signalling rationale sought to reduce tumour-promoting pathways, but cell bias is not a carcinogenicity study. Long-term animal toxicology would need to examine tumour initiation, progression, immune effects and tissue remodelling before human reassurance was justified.
Has B7-33 been tested in humans?
No published human exposure study or B7-33-specific registered clinical trial was identifiable as of October 2026. There is no established human dose, bioavailability, half-life or clinical outcome.
This is a stronger limitation than “limited evidence”. Every therapeutic claim currently depends on cells, isolated vessels, rodents or engineered delivery systems.
Is B7-33 approved?
No. B7-33 is not approved by the FDA, MHRA or EMA for fibrosis, heart failure, kidney disease, lung disease, wound healing or any other indication.
Its relationship to a natural hormone and to a clinically studied recombinant protein does not confer approval. No authorised B7-33 product label or reference formulation exists.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does B7-33 activate RXFP1? | Receptor assays and pathway studies | Yes, with lower affinity and context-dependent signalling bias |
| Does it alter fibrosis? | Several rodent organ and implant models | Anti-fibrotic activity is plausible preclinically |
| Does it protect the heart? | Mouse infarction and rodent cardiomyopathy studies | Selected acute and remodelling outcomes improved in animals |
| Does it treat human fibrosis or heart failure? | No human trial | Unknown |
| Is it safer than serelaxin? | Cell-signalling rationale, no comparative human safety data | Not established |
| Is there a validated human dose? | No human pharmacokinetic study | No |
| Is it approved? | No regulatory approval | No |
B7-33 is a credible research scaffold, not a clinical therapy. The most important next experiment is not another commercial claim but a formal development package connecting product quality, toxicology, exposure and human safety.
What claims are not established?
B7-33 has not been shown to reverse fibrosis in people, repair organs, prevent heart failure, treat kidney disease, improve asthma or accelerate recovery from injury. It has no evidence-based cycle, stack or self-administration protocol.
Combining it with BPC-157, TB-500, growth factors or other research peptides has no controlled human evidence. A theoretical pathway combination does not demonstrate additive benefit or safety.
Frequently asked questions
Is B7-33 a peptide?
Yes. It is a synthetic linear peptide containing 27 amino-acid residues.
What is B7-33 derived from?
It was designed from the B-chain of human relaxin-2, with truncation and extension used to create a single active chain.
What receptor does B7-33 activate?
It activates relaxin family peptide receptor 1, or RXFP1.
What is biased agonism?
It means a ligand favours some signalling outputs from a receptor over others. B7-33 showed ERK-favouring behaviour in selected cells with natural RXFP1 expression.
Is B7-33 the same as relaxin-2?
No. Natural relaxin-2 is a two-chain hormone connected by disulphide bonds. B7-33 is a shorter single-chain analogue.
Is B7-33 the same as serelaxin?
No. Serelaxin is recombinant human relaxin-2 and has a separate human clinical record.
Has B7-33 been tested in humans?
No published human trial or human pharmacokinetic study was identifiable as of October 2026.
Does B7-33 reduce fibrosis?
It reduced fibrosis-related measurements in several rodent models. Human clinical benefit has not been established.
Can B7-33 treat heart failure?
No. Animal cardiac studies are encouraging, but no human heart-failure trial has tested it.
Does B7-33 treat pulmonary fibrosis?
Airway and lung fibrosis improved in a chronic allergic-airway mouse model. That is not evidence for treatment of human pulmonary fibrosis.
What is the half-life of B7-33?
One in-vitro serum study reported about six minutes for unmodified B7-33. Human in-vivo pharmacokinetics are unknown.
Is lipidated B7-33 the same compound?
No. Adding a fatty acid and spacer creates a modified analogue with different stability and potentially different distribution.
Is B7-33 safer than full-length relaxin?
That has not been established. Pathway bias in cells is not a substitute for comparative toxicology or human safety trials.
Is B7-33 FDA approved?
No. It is not an approved medicine for any indication.
Can animal doses be converted into human use?
No reliable clinical protocol can be derived by scaling rodent exposure. Human absorption, clearance, receptor engagement and safety are unknown.
What would convincing future research require?
Development would begin with a defined pharmaceutical formulation, validated potency assay and toxicology covering cardiovascular, renal, reproductive, wound-healing and tumour-related risks. Human Phase I research would then need to establish pharmacokinetics, tolerability and receptor-relevant biomarkers.
Later trials would need organ-specific outcomes. A heart programme should measure function, hospitalisation and survival; a lung programme should measure symptoms and physiology; a kidney programme should measure filtration and progression. Collagen staining alone would not be enough.
The bottom line
B7-33 is an intelligently designed relaxin-2 derivative that simplified a complex two-chain hormone into a single RXFP1-active peptide. Its functionally selective signalling and repeated anti-fibrotic animal findings make it scientifically interesting.
The translation gap is nevertheless complete. There are no published human data, no validated clinical dose and no approved product. Even serelaxin, with extensive human development, failed to improve the confirmatory endpoints in a 6,545-person heart-failure trial.
B7-33 should therefore be presented as a preclinical receptor and fibrosis research tool, not as an established repair peptide or treatment.
Research notice
This guide is educational. It does not provide dosing, preparation, administration, cycling, stacking or purchasing guidance.
Sources
Research reviewed through October 2026.